Aster DM Healthcare announced a strong Q3 FY26 performance, with revenues up by 13% YoY to INR 1,186 Crs. The combined proforma of Aster and Quality Care India Ltd shows revenues up by 15% to INR 2,366 Crs. Operating EBITDA (ex-Kasaragod) grew by 17% YoY to INR 237 Crs. Shareholders’ meeting to be convened between Feb 27 and Mar 13, 2026.
Q3 FY26 Financial Highlights
Aster DM Healthcare reported the following key financial results for Q3 FY26:
- Revenue increased by 13% YoY to INR 1,186 Crs.
- Operating EBITDA (excluding Kasaragod) grew by 17% YoY to INR 237 Crs.
- Operating EBITDA Margin (excluding Kasaragod) stood at 20.2%, compared to 19.3% in Q3 FY25.
- Normalised PAT (excluding Kasaragod) increased by 22% YoY to INR 98 Crs.
Combined Proforma Performance (Aster + QCIL)
The combined performance of Aster and Quality Care India Ltd (QCIL) for Q3 FY26 shows:
- Revenue grew by 15% to INR 2,366 Cr.
- Operating EBITDA increased by 22% to INR 503 Cr.
- Operating EBITDA margin was 21%.
Operational Performance
The combined entity has added over 560 beds in the past year, bringing the total combined capacity to 10,620 beds across 28 cities. A pipeline of more than 4,000 additional beds is planned to support long-term growth.
India Business Performance
Overall, the India business showed double-digit YoY growth in revenue and operating EBITDA, driven by growth in Kerala, strong international revenue, and a better case mix.
- ARPP IP rose 9% YoY to INR 1,22,294 in Q3 FY26.
- Total patient volume grew by 10% YoY.
Core Hospital Business
- Core hospitals & clinics delivered an Operating EBITDA margin of 21.4% in Q3 FY26 (22.8% excluding Kasargod).
- Aster Medcity revenue grew by 24% YoY and Operating EBITDA grew by 33% YoY.
Merger Update
The company has completed the preferential allotment of approximately 3.6% stake to Blackstone and TPG. The shareholders’ meeting is scheduled between February 27, 2026, and March 13, 2026.
Source: BSE
